(RMD) ResMed - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7611521078

RMD: Medical Devices, Software Applications

ResMed Inc. (NYSE: RMD) is a global leader in developing, manufacturing, and distributing medical devices and cloud-based software solutions for the healthcare industry. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its product portfolio includes advanced diagnostic tools such as ApneaLink Air, a portable device that measures multiple physiological parameters for sleep apnea diagnosis, and NightOwl, a cloud-connected, disposable diagnostic device that assesses AHI using peripheral arterial tone, actigraphy, and oximetry over several nights. ResMed also offers a suite of software solutions like AirView, which enables remote patient monitoring and device setting adjustments, and myAir, a patient engagement app designed to improve therapy adherence for sleep apnea patients. Additionally, the company provides U-Sleep, a compliance monitoring solution for home medical equipment providers, and Propeller, a connectivity module and portal for enhanced disease management.

ResMeds out-of-hospital software solutions include Brightree, a comprehensive business management platform for home medical equipment, pharmacy, and home infusion providers; MatrixCare, which offers care management solutions for senior living and skilled nursing facilities; HEALTHCAREfirst, providing electronic health records, billing, and analytics for home health and hospice agencies; and MEDIFOX DANs software solutions. The company distributes its products through a network of distributors and direct salesforce, targeting sleep clinics, home healthcare dealers, and hospitals. Founded in 1989 and headquartered in San Diego, California, ResMed has established itself as a key player in the healthcare technology sector. Web URL: https://www.resmed.com

Ticker Symbol: RMD Exchange: NYSE Type: common stock Country Origin: United States GICS Sub Industry: Health Care Equipment Based on the provided and , ResMed Inc. is expected to experience a mixed outlook over the next three months. The stocks current price of 212.91 is below its SMA20 (216.37) and SMA50 (224.79), suggesting potential short-term weakness. However, the SMA200 (230.83) indicates longer-term support. The ATR of 7.86 suggests moderate volatility. Fundamentally, ResMeds P/E of 25.14 and forward P/E of 20.79 indicate expectations of earnings growth. The companys RoE of 23.77% reflects strong profitability. Given these factors, ResMeds stock may consolidate in the near term, with potential support around the SMA200 level.

Additional Sources for RMD Stock

RMD Stock Overview

Market Cap in USD 34,363m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception 1995-06-02

RMD Stock Ratings

Growth Rating 28.5
Fundamental 93.0
Dividend Rating 55.5
Rel. Strength 9.6
Analysts 3.72/5
Fair Price Momentum 219.86 USD
Fair Price DCF 206.18 USD

RMD Dividends

Dividend Yield 12m 0.88%
Yield on Cost 5y 1.36%
Annual Growth 5y 5.30%
Payout Consistency 100.0%

RMD Growth Ratios

Growth Correlation 3m -70.4%
Growth Correlation 12m 37.3%
Growth Correlation 5y 17.9%
CAGR 5y 9.29%
CAGR/Max DD 5y 0.17
Sharpe Ratio 12m 0.44
Alpha 1.63
Beta 0.788
Volatility 59.70%
Current Volume 718.1k
Average Volume 20d 1439k
What is the price of RMD stocks?
As of May 01, 2025, the stock is trading at USD 237.74 with a total of 718,085 shares traded.
Over the past week, the price has changed by +11.05%, over one month by +6.21%, over three months by -5.77% and over the past year by +10.45%.
Is ResMed a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, ResMed (NYSE:RMD) is currently (May 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 92.96 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RMD as of May 2025 is 219.86. This means that RMD is currently overvalued and has a potential downside of -7.52%.
Is RMD a buy, sell or hold?
ResMed has received a consensus analysts rating of 3.72. Therefor, it is recommend to hold RMD.
  • Strong Buy: 6
  • Buy: 3
  • Hold: 8
  • Sell: 0
  • Strong Sell: 1
What are the forecast for RMD stock price target?
According to ValueRays Forecast Model, RMD ResMed will be worth about 244.9 in May 2026. The stock is currently trading at 237.74. This means that the stock has a potential upside of +3.02%.
Issuer Forecast Upside
Wallstreet Target Price 263.2 10.7%
Analysts Target Price 256 7.7%
ValueRay Target Price 244.9 3%